Fred Hutchinson Cancer Research Center, Seattle, WA
Catherine R. Fedorenko, Laura Elizabeth Panattoni, Qin Sun, Li Li, Karma L. Kreizenbeck, Scott David Ramsey
Background: Rural residents are diagnosed at later stages of cancer compared to urban residents, have poorer survival, and face distinct barriers to receiving quality cancer care. ASCO has developed policy initiatives to address rural cancer care; however, little is known about quality of cancer care among patients residing in rural areas. This study examined the impact of rurality on performance metrics, controlling for socioeconomic status and insurance type. Methods: We linked Washington state cancer registry records from 2015-2017 with claims records for two large commercial insurers, Medicare, and Medicaid. Using claims from this database, we generated eight nationally recognized quality measures. Rurality was measured by the Rural-Urban Commuting Area Codes (RUCAs) categorized into 4 levels (Metro, Metro with commute, Micropolitan, Small Town/Rural). Process and outcome measures were adjusted for age, sex, race, comorbidity score, stage, cancer type, marital status, the Area Deprivation Index, and treatment factors where appropriate. Results were stratified by payer type. Results: The table below lists the effect of a patient’s rurality on the quality metric where significant (p<0.05). Where rurality did not impact the performance measure, results are left blank. Conclusions: After controlling for socioeconomic status and payer type, quality of cancer care for rural cancer patients was not consistently poorer compared to urban patients. These results suggest that lower survival among rural patients may be due to factors beyond quality of care.
N | Commercial | Medicare | Low Income Insurance* | |
---|---|---|---|---|
Outcome measures | ||||
Emergency department (ED) visits during chemotherapy | 8730 | |||
Inpatient stays during chemotherapy | 8730 | 0.63 | 0.52 | |
End of Life (EoL): 2+ ED visits | 10468 | Metro commute: 0.69 | ||
EoL: ICU stay | 10468 | 0.66 | Metro commute: 0.59 Micro: 0.55 0.47 | |
Process measures | ||||
Recommended Treatment | 3091 | |||
Anti-nausea medication during chemotherapy | 4072 | Micro: 0.27 | ||
EoL: Chemotherapy | 10468 | |||
EoL: Hospice | 10468 | Micro: 0.74 |
*Low income insurance = Medicaid, Medicare under 65 (disabled), Medicaid/Medicare dual enrolled
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Abstract Disclosures
2023 ASCO Annual Meeting
First Author: Victoria Wu
2022 ASCO Annual Meeting
First Author: Timothy James Daeeun Ohlsen
2023 ASCO Annual Meeting
First Author: Vernon Wu
2023 ASCO Annual Meeting
First Author: Dawn L. Hershman